CN115066424A - Kv3调节剂 - Google Patents

Kv3调节剂 Download PDF

Info

Publication number
CN115066424A
CN115066424A CN202080095972.7A CN202080095972A CN115066424A CN 115066424 A CN115066424 A CN 115066424A CN 202080095972 A CN202080095972 A CN 202080095972A CN 115066424 A CN115066424 A CN 115066424A
Authority
CN
China
Prior art keywords
compound
disorders
benzofuran
dione
imidazolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095972.7A
Other languages
English (en)
Chinese (zh)
Inventor
G·阿尔瓦罗
A·马拉斯科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autifony Therapeutics Ltd
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of CN115066424A publication Critical patent/CN115066424A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
CN202080095972.7A 2020-02-06 2020-02-06 Kv3调节剂 Pending CN115066424A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2020/050268 WO2021156584A1 (fr) 2020-02-06 2020-02-06 Modulateurs de kv3

Publications (1)

Publication Number Publication Date
CN115066424A true CN115066424A (zh) 2022-09-16

Family

ID=69591671

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095972.7A Pending CN115066424A (zh) 2020-02-06 2020-02-06 Kv3调节剂

Country Status (11)

Country Link
EP (1) EP4100402A1 (fr)
JP (1) JP2023523501A (fr)
KR (1) KR20220139923A (fr)
CN (1) CN115066424A (fr)
AU (1) AU2020427632A1 (fr)
BR (1) BR112022013339A2 (fr)
CA (1) CA3169057A1 (fr)
CL (1) CL2022002081A1 (fr)
IL (1) IL295027A (fr)
MX (1) MX2022009702A (fr)
WO (1) WO2021156584A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117448440A (zh) * 2023-10-23 2024-01-26 中国人民解放军空军军医大学 Kv3在制备诊断或治疗创伤后应激障碍异常恐惧记忆消退产品中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013083994A1 (fr) * 2011-12-06 2013-06-13 Autifony Therapeutics Limited Dérivés d'hydantoïne utiles comme inhibiteurs de kv3
CN103328467A (zh) * 2010-12-06 2013-09-25 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
WO2013182851A1 (fr) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxie ou traitement de maladies dans lesquelles un modulateur des canaux kv3.3 est requis
WO2018109484A1 (fr) * 2016-12-16 2018-06-21 Autifony Therapeutics Limited Modulateurs d'hydantoïne de canaux kv3
CN108430995A (zh) * 2015-12-16 2018-08-21 奥提芙尼治疗学有限公司 新型化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019970B8 (ru) 2009-12-11 2014-11-28 Отифони Терапеутикс Лимитед Производные имидазолидиндиона
WO2012168710A1 (fr) 2011-06-07 2012-12-13 Autifony Therapeutics Limited Dérivés d'hydantoïne en tant qu'inhibiteurs de kv3
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
BR112014028718A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
EP2852589B1 (fr) 2012-05-22 2021-04-28 Autifony Therapeutics Limited Triazoles en tant qu'inhibiteurs de kv3
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
EP3853216A4 (fr) 2018-09-21 2022-08-10 Bionomics Limited Composés substitués par pyridinyle et leurs utilisations
BR112021006940A2 (pt) * 2018-10-16 2021-07-13 Autifony Therapeutics Limited compostos
US20220112176A1 (en) 2019-03-25 2022-04-14 Bionomics Limited Substituted-n-heteroaryl compounds and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328467A (zh) * 2010-12-06 2013-09-25 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
WO2013083994A1 (fr) * 2011-12-06 2013-06-13 Autifony Therapeutics Limited Dérivés d'hydantoïne utiles comme inhibiteurs de kv3
WO2013182851A1 (fr) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxie ou traitement de maladies dans lesquelles un modulateur des canaux kv3.3 est requis
CN108430995A (zh) * 2015-12-16 2018-08-21 奥提芙尼治疗学有限公司 新型化合物
WO2018109484A1 (fr) * 2016-12-16 2018-06-21 Autifony Therapeutics Limited Modulateurs d'hydantoïne de canaux kv3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李仁利: "《药物构效关系》", 北京：中国医药科技出版社, pages: 182 - 184 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117448440A (zh) * 2023-10-23 2024-01-26 中国人民解放军空军军医大学 Kv3在制备诊断或治疗创伤后应激障碍异常恐惧记忆消退产品中的应用

Also Published As

Publication number Publication date
KR20220139923A (ko) 2022-10-17
AU2020427632A1 (en) 2022-08-18
WO2021156584A1 (fr) 2021-08-12
MX2022009702A (es) 2022-09-07
CA3169057A1 (fr) 2021-08-12
CL2022002081A1 (es) 2023-05-26
EP4100402A1 (fr) 2022-12-14
IL295027A (en) 2022-09-01
BR112022013339A2 (pt) 2022-09-13
JP2023523501A (ja) 2023-06-06

Similar Documents

Publication Publication Date Title
US11541052B2 (en) Compounds
JP7036725B2 (ja) Ｋｖ３チャネルのヒダントインモジュレーター
JP6240667B2 (ja) Ｋｖ３阻害剤としてのトリアゾール
JP6008953B2 (ja) Ｋｖ３阻害剤としてのヒダントイン誘導体
JP5985651B2 (ja) Ｋｖ３阻害剤として有用なヒダントイン誘導体
EP3490977B1 (fr) Dérivés cyclobutane comme modulateurs des canaux potassiques voltage-dépendants
TWI827706B (zh) 新穎化合物
US20200039970A1 (en) Hydantoin modulators of kv3 channels
CN115066424A (zh) Kv3调节剂
US20210276985A1 (en) Novel compounds
CN117751119A (zh) 钾通道调节剂
BR112014013400B1 (pt) Compostos derivados de hidantoína úteis como inibidores de kv3 e seus usos na profilaxia ou tratamento de distúrbios auditivos e esquizofrenia ou no tratamento de síndrome do x frágil

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081003

Country of ref document: HK